IL296659A - Cancer treatment methods and the use of biomarkers to predict clinical sensitivity to treatments - Google Patents

Cancer treatment methods and the use of biomarkers to predict clinical sensitivity to treatments

Info

Publication number
IL296659A
IL296659A IL296659A IL29665922A IL296659A IL 296659 A IL296659 A IL 296659A IL 296659 A IL296659 A IL 296659A IL 29665922 A IL29665922 A IL 29665922A IL 296659 A IL296659 A IL 296659A
Authority
IL
Israel
Prior art keywords
biomarker
compound
optionally substituted
level
sample
Prior art date
Application number
IL296659A
Other languages
English (en)
Hebrew (he)
Inventor
Ellen Filvaroff
Antonia Lopez-Girona
Gang Lu
Original Assignee
Celgene Corp
Ellen Filvaroff
Lopez Girona Antonia
Gang Lu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Ellen Filvaroff, Lopez Girona Antonia, Gang Lu filed Critical Celgene Corp
Publication of IL296659A publication Critical patent/IL296659A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL296659A 2016-01-08 2017-01-06 Cancer treatment methods and the use of biomarkers to predict clinical sensitivity to treatments IL296659A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662276700P 2016-01-08 2016-01-08
US201662404638P 2016-10-05 2016-10-05
PCT/US2017/012496 WO2017120446A1 (en) 2016-01-08 2017-01-06 Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies

Publications (1)

Publication Number Publication Date
IL296659A true IL296659A (en) 2022-11-01

Family

ID=59274055

Family Applications (2)

Application Number Title Priority Date Filing Date
IL296659A IL296659A (en) 2016-01-08 2017-01-06 Cancer treatment methods and the use of biomarkers to predict clinical sensitivity to treatments
IL260400A IL260400B2 (en) 2016-01-08 2018-07-03 Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL260400A IL260400B2 (en) 2016-01-08 2018-07-03 Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies

Country Status (10)

Country Link
US (3) US10648983B2 (cg-RX-API-DMAC7.html)
EP (1) EP3399980B1 (cg-RX-API-DMAC7.html)
JP (3) JP6880037B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180095094A (cg-RX-API-DMAC7.html)
AU (1) AU2017205170B2 (cg-RX-API-DMAC7.html)
CA (1) CA3010801A1 (cg-RX-API-DMAC7.html)
ES (1) ES3042541T3 (cg-RX-API-DMAC7.html)
IL (2) IL296659A (cg-RX-API-DMAC7.html)
MX (1) MX390772B (cg-RX-API-DMAC7.html)
WO (1) WO2017120446A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015085172A2 (en) 2013-12-06 2015-06-11 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
US10338077B2 (en) 2015-06-02 2019-07-02 Celgene Corporation Methods for determining drug efficacy for treatment of cancer ration of cereblon associated proteins
KR20180052747A (ko) 2015-09-25 2018-05-18 셀진 코포레이션 미만성 거대 b세포 림프종의 치료 방법 및 약물에 대한 반응성의 예측자로서 바이오마커의 용도
US10648983B2 (en) 2016-01-08 2020-05-12 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
US11525165B2 (en) 2017-12-20 2022-12-13 Inserm Method of selection of an IRE1-inhibitor therapy for patient suffering from cancer
JP2021519786A (ja) 2018-03-30 2021-08-12 バイオセリックス， インコーポレイテッド チエノピリミジノン化合物
KR102718800B1 (ko) * 2018-05-23 2024-10-18 셀진 코포레이션 다발성 골수종의 치료 및 4-(4-(4-(((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-4-일)옥시)메틸)벤질)피페라진-1-일)-3-플루오로벤조니트릴에 대한 바이오마커의 용도
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2021047627A1 (zh) * 2019-09-12 2021-03-18 南京明德新药研发有限公司 一种可降解蛋白的并环类化合物及其应用
MX2022004984A (es) * 2019-10-28 2022-05-13 Celgene Corp Metodos para tratar leucemia y uso de una firma de celulas madre leucemicas para predecir sensibilidad clinica a terapias.
CA3156232A1 (en) * 2019-10-28 2021-05-06 Gang Lu Use of biomarkers to predict clinical sensitivity to 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
US11031119B2 (en) * 2019-11-13 2021-06-08 Cube Click, Inc. Dental images processed with deep learning for national security
CN114761004A (zh) * 2019-12-06 2022-07-15 细胞基因公司 用于制备2-(4-氯苯基)-n-((2-(2，6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2，2-二氟乙酰胺的方法
KR102311390B1 (ko) * 2020-03-03 2021-10-13 이화여자대학교 산학협력단 교모세포종 예후예측용 조성물
IL296557A (en) * 2020-03-16 2022-11-01 Celgene Corp Combined treatment for acute myeloid leukemia
WO2021211742A1 (en) * 2020-04-14 2021-10-21 The General Hospital Corporation Use of gcn2 inhibitors in treating mitochondrial myopathies and diseases associated with mitochondrial dysfunction
MX2022016498A (es) 2020-06-25 2023-02-23 Tolremo Therapeutics Ag Una combinacion de un inhibidor de cbp/p300 bromodominio y un inhibidor de kras.
KR102499522B1 (ko) 2020-09-23 2023-02-13 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드 세레브론 단백질의 조절제로서의 치환된 n-(2-(2,6-디옥소피페리딘-3-일)-1,3-디옥소이소인돌린-5-일)아릴설폰아미드 유사체
EP4278014A1 (en) * 2021-01-13 2023-11-22 Monte Rosa Therapeutics, Inc. Treatment of myc-driven cancers with gspt1 degraders
JP2024504932A (ja) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス， インコーポレイテッド イソインドリノン化合物
GB202104635D0 (en) * 2021-03-31 2021-05-12 Imperial College Innovations Ltd Methods and compositions for identifying and treating GCN2-dependent cancers
JP2024515061A (ja) * 2021-04-07 2024-04-04 トルレモ・セラピューティクス・アクチェンゲゼルシャフト 複素環誘導体、医薬組成物およびがんの治療または軽快におけるこれらの使用
EP4323349A1 (en) * 2021-04-14 2024-02-21 Monte Rosa Therapeutics AG Isoindolinone amide compounds useful to treat diseases associated with gspt1
KR102823538B1 (ko) 2021-11-09 2025-06-23 한국화학연구원 글루타이미드 모핵을 갖는 이소인돌리논 유도체 및 이의 용도
JP2024544507A (ja) 2021-11-09 2024-12-03 コリア リサーチ インスティテュート オブ ケミカル テクノロジー グルタルイミド母核を有するイソインドリノン誘導体及びその用途
CN114660289A (zh) * 2022-03-03 2022-06-24 中山大学附属第三医院 肝癌标志物及其应用
US12187699B2 (en) * 2022-04-14 2025-01-07 Bristol-Myers Squibb Company GSPT1 compounds and methods of use of the novel compounds
US20240115557A1 (en) * 2022-07-29 2024-04-11 The Brigham And Women's Hospital, Inc. Inhibitors of rna-guided nucleases and uses thereof
EP4587042A1 (en) * 2022-09-16 2025-07-23 Temple University of the Commonwealth System of Higher Education Bag 3 methods and uses for treatment of cardiac amyloidosis
KR20240066904A (ko) 2022-11-08 2024-05-16 주식회사 온코드바이오 아릴시클로알킬아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도
KR20240066906A (ko) 2022-11-08 2024-05-16 주식회사 온코드바이오 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도
KR102570883B1 (ko) * 2023-04-13 2023-08-29 (주) 사이러스테라퓨틱스 신규한 gspt1 분해제 및 이의 용도
WO2025164957A1 (ko) * 2024-01-31 2025-08-07 남부대학교산학협력단 인간화된 세레브론 넉인 마우스 모델 및 이를 이용한 다발성 골수종 항암화학요법의 효능 평가 방법

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1574740A (en) * 1924-04-07 1926-02-23 Raynor John Roscoe Cutting device
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE69330750T2 (de) 1992-03-04 2002-07-04 The Regents Of The University Of California, Oakland Vergleichende genomhybridisierung
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
WO1998027980A2 (en) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0103527D0 (en) 2001-02-13 2001-03-28 Eastman Kodak Co Photographic developing composition and use thereof in the development of a photographic element
US7122799B2 (en) 2003-12-18 2006-10-17 Palo Alto Research Center Incorporated LED or laser enabled real-time PCR system and spectrophotometer
CN101180407A (zh) * 2005-05-18 2008-05-14 惠氏公司 白血病疾病基因和其用途
EP3354646A1 (en) 2008-10-29 2018-08-01 Celgene Corporation Isoindoline compounds for use in the treatment of cancer
JP2013522236A (ja) * 2010-03-12 2013-06-13 セルジーン コーポレイション レナリドミドを使用する非ホジキンリンパ腫の治療方法、並びに予測因子としての遺伝子及びタンパク質バイオマーカー
AU2012236655B2 (en) 2011-03-28 2016-09-22 Deuterx, Llc, 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
WO2012149299A2 (en) 2011-04-29 2012-11-01 Celgene Corporaiton Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
JP6318152B2 (ja) 2012-06-29 2018-04-25 セルジーン コーポレイション セレブロン関連タンパク質を利用して薬物効能を決定する方法
US9119854B2 (en) 2013-05-03 2015-09-01 Celgene Corporation Methods for treating cancer using combination therapy
BR112016012792A2 (pt) 2013-12-06 2017-08-08 Celgene Corp Métodos para o tratamento de cânceres hematológicos e o uso de biomarcadores como um preditor de sensibilidade clínica a terapias imunomoduladoras
WO2015085172A2 (en) 2013-12-06 2015-06-11 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
US9499514B2 (en) * 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
WO2016060702A1 (en) 2014-10-13 2016-04-21 Celgene Corporaton Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
US10338077B2 (en) 2015-06-02 2019-07-02 Celgene Corporation Methods for determining drug efficacy for treatment of cancer ration of cereblon associated proteins
JP2018523823A (ja) 2015-08-04 2018-08-23 セルジーン コーポレイション 慢性リンパ球性白血病の治療方法及び免疫調節療法に対する臨床的感度の予測因子としてのバイオマーカーの利用
EP3334844A4 (en) 2015-08-12 2019-11-06 Celgene Corporation METHOD FOR THE TREATMENT OF SOLID TUMORS AND USE OF BIOMARKERS AS PREDICTORS OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES
KR20180052747A (ko) 2015-09-25 2018-05-18 셀진 코포레이션 미만성 거대 b세포 림프종의 치료 방법 및 약물에 대한 반응성의 예측자로서 바이오마커의 용도
MX382150B (es) * 2016-01-08 2025-03-13 Celgene Corp Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida.
US10648983B2 (en) 2016-01-08 2020-05-12 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
MX385964B (es) * 2016-01-08 2025-03-18 Celgene Corp Formas sólidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il) metil)-2,2-difluoroacetamida y sus composiciones farmacéuticas y usos.
KR20190015300A (ko) * 2016-06-06 2019-02-13 셀진 코포레이션 2-(4-클로로페닐)-n-((2-(2,6-다이옥소피페리딘-3-일)-1-옥소아이소인돌린-5-일)메틸)-2,2-다이플루오로아세트아마이드에 의한 혈액 악성종양의 치료

Also Published As

Publication number Publication date
JP2019504063A (ja) 2019-02-14
US11460471B2 (en) 2022-10-04
WO2017120446A1 (en) 2017-07-13
JP7113942B2 (ja) 2022-08-05
EP3399980A1 (en) 2018-11-14
EP3399980A4 (en) 2019-09-04
JP6880037B2 (ja) 2021-06-02
IL260400A (cg-RX-API-DMAC7.html) 2018-08-30
AU2017205170B2 (en) 2021-06-24
US10648983B2 (en) 2020-05-12
US20200333340A1 (en) 2020-10-22
KR20180095094A (ko) 2018-08-24
US20230064156A1 (en) 2023-03-02
AU2017205170A1 (en) 2018-07-19
MX2018008421A (es) 2019-12-09
EP3399980B1 (en) 2025-07-16
US12474342B2 (en) 2025-11-18
MX390772B (es) 2025-03-21
JP2021121799A (ja) 2021-08-26
IL260400B (en) 2022-10-01
IL260400B2 (en) 2023-02-01
US20170199193A1 (en) 2017-07-13
JP2022166014A (ja) 2022-11-01
ES3042541T3 (en) 2025-11-21
CA3010801A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
US12474342B2 (en) Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
JP2019504063A5 (cg-RX-API-DMAC7.html)
US20180267043A1 (en) Use of biomarkers for predicting clinical sensitivity to cancer treatment
TWI653977B (zh) 利用３－（４－（（４－（嗎啉基甲基）苄基）氧基）－１－氧異吲哚啉－２－基）六氫吡啶－２，６－二酮治療癌症之方法
KR102299801B1 (ko) 미만성 거대 b-세포 림프종, 다발성 골수종, 및 골수암의 치료를 위한 약물 효능을 결정하는 방법
JP6585737B2 (ja) セレブロン関連タンパク質の比を使用してがんの治療のための薬物の有効性を決定するための方法
JP7662625B2 (ja) 血液がんの治療方法ならびに２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンに対するコンパニオンバイオマーカーの使用
CN103688176A (zh) 利用cereblon作为预报因子治疗癌和炎性疾病的方法
KR20180005174A (ko) 단백질을 표적하는 화합물, 조성물, 방법, 및 그의 용도
WO2017024019A1 (en) Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
US20250032502A1 (en) Methods for treating systemic lupus erythematosus and the use of biomarkers as a predictor of clinical sensitivity to therapies
HK1195622A (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
NZ714846A (en) Treatment of cancers using pi3 kinase isoform modulators